Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2015

01.09.2015 | Colorectal Cancer

Medullary Colorectal Carcinoma Revisited: A Clinical and Pathological Study of 102 Cases

verfasst von: Robert D. Knox, MBBS, Nathan Luey, BSc, Loretta Sioson, BSc, Andrew Kedziora, FRCPA, Adele Clarkson, BSc, Nicole Watson, Christopher W. Toon, FRCPA, Carmen Cussigh, Stuart Pincott, FRACS, Stephen Pillinger, FRACS, Yasser Salama, FRACS, Justin Evans, FRACS, John Percy, FRACS, Margaret Schnitzler, PhD, FRACS, Alexander Engel, PhD, FRACS, Anthony J. Gill, MD, FRCPA

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Aim

Medullary carcinoma is a recently described subtype of mismatch repair deficient (MMRd) colorectal carcinoma (CRC) which, despite being poorly differentiated by traditional morphological criteria, has been reported to have a good prognosis. We investigated the pathological and clinical features of medullary CRC in an unselected cohort of CRCs undergoing surgical resection.

Methods

All CRCs resected within a single health district database from 1998 to 2012 were categorized prospectively and underwent retrospective review to identify 91 medullary CRCs, with 11 additional cases from 2013 to 2014. Strict criteria were employed to diagnose medullary carcinoma requiring both MMRd and greater than 90 % of the tumor to demonstrate typical morphology, including solid growth. The demographic and pathological features, as well as all-cause survival, were compared with other CRCs, and specifically to other MMRd CRCs.

Results

From 1998 to 2012, 91 of 3,295 CRCs (2.8 %) were of the medullary type. Medullary CRC was more likely to arise in females than males (3.3:1; p < 0.0001), the elderly (mean age 77 vs. 71 years; p < 0.001), and the right colon (86 %; p < 0.0001). All medullary CRCs demonstrated MMR deficiency (considered an inclusion criteria) and 86 % were BRAFV600E-mutated (p < 0.0001). Thirty-day mortality after resection was higher in medullary CRC (4.6 vs. 1.7 %; p = 0.049). On univariate analysis, survival was not better than well-differentiated or other MMRd tumors. However, using a multivariate model, a medullary phenotype was protective (hazard ratio of death 0.54, 95 % CI 0.30–0.96; p = 0.037).

Conclusions

Medullary CRC is more common than previously reported, frequently presents with locally advanced disease, and may be associated with higher mortality at 30 days after resection. Despite this, when strict criteria are used for diagnosis, the overall survival is favorable when compared with CRCs with equivalent demographic and pathological characteristics.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
3.
Zurück zum Zitat Thirunavukarasu P, Sathaiah M. Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol. 2010;37:901–7.PubMedCentralPubMed Thirunavukarasu P, Sathaiah M. Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol. 2010;37:901–7.PubMedCentralPubMed
4.
Zurück zum Zitat Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3:153–73.PubMedCentralPubMed Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3:153–73.PubMedCentralPubMed
5.
Zurück zum Zitat Hamilton SR, Bosman FT, Boffetta P, et al. Carcinoma of the colon and rectum. In: Hamilton SR, Aaltonen LA, editors. WHO classification of tumours of the digestive system. Lyon: IARC Press, 2010:134–46. Hamilton SR, Bosman FT, Boffetta P, et al. Carcinoma of the colon and rectum. In: Hamilton SR, Aaltonen LA, editors. WHO classification of tumours of the digestive system. Lyon: IARC Press, 2010:134–46.
6.
Zurück zum Zitat Rüschoff J, Dietmaier W, Lüttges J, Seitz G. Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol. 1997;150:1815–25.PubMedCentralPubMed Rüschoff J, Dietmaier W, Lüttges J, Seitz G. Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol. 1997;150:1815–25.PubMedCentralPubMed
7.
Zurück zum Zitat Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527–35.PubMedCentralPubMedCrossRef Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527–35.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Arai T, Kasahara I, Sawabe M. Microsatellite‐unstable mucinous colorectal carcinoma occurring in the elderly: comparison with medullary type poorly differentiated adenocarcinoma. Pathology. 2007;57:205–12. Arai T, Kasahara I, Sawabe M. Microsatelliteunstable mucinous colorectal carcinoma occurring in the elderly: comparison with medullary type poorly differentiated adenocarcinoma. Pathology. 2007;57:205–12.
9.
Zurück zum Zitat Arai T, Esaki Y, Sawabe M, Honma N, Nakamura K-I, Takubo K. Hypermethylation of the hMLH1 promoter with absent hMLH1 expression in medullary-type poorly differentiated colorectal adenocarcinoma in the elderly. Mod Pathol. 2004;17:172–9.PubMedCrossRef Arai T, Esaki Y, Sawabe M, Honma N, Nakamura K-I, Takubo K. Hypermethylation of the hMLH1 promoter with absent hMLH1 expression in medullary-type poorly differentiated colorectal adenocarcinoma in the elderly. Mod Pathol. 2004;17:172–9.PubMedCrossRef
10.
Zurück zum Zitat Lanza G, Gafà R, Matteuzzi M, Santini A. Medullary-type poorly differentiated adenocarcinoma of the large bowel: a distinct clinicopathologic entity characterized by microsatellite instability and improved survival. J Clin Oncol. 1999;17:2429–38.PubMed Lanza G, Gafà R, Matteuzzi M, Santini A. Medullary-type poorly differentiated adenocarcinoma of the large bowel: a distinct clinicopathologic entity characterized by microsatellite instability and improved survival. J Clin Oncol. 1999;17:2429–38.PubMed
11.
Zurück zum Zitat Hinoi T, Tani M, Lucas PC, et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001;159:2239–48.PubMedCentralPubMedCrossRef Hinoi T, Tani M, Lucas PC, et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001;159:2239–48.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Wick MR, Vitsky JL, Ritter JH. Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am J Clin Pathol. 2005;123:56–65.PubMedCrossRef Wick MR, Vitsky JL, Ritter JH. Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am J Clin Pathol. 2005;123:56–65.PubMedCrossRef
13.
Zurück zum Zitat Jessurun J, Romero-Guadarrama M, Manivel JC. Medullary adenocarcinoma of the colon: clinicopathologic study of 11 cases. Hum Pathol. 1999;30:843–8.PubMedCrossRef Jessurun J, Romero-Guadarrama M, Manivel JC. Medullary adenocarcinoma of the colon: clinicopathologic study of 11 cases. Hum Pathol. 1999;30:843–8.PubMedCrossRef
14.
Zurück zum Zitat Winn B, Tavares R, Fanion J, Noble L, Gao J, Sabo E. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation. Hum Pathol. 2009;40:398–404.PubMedCentralPubMedCrossRef Winn B, Tavares R, Fanion J, Noble L, Gao J, Sabo E. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation. Hum Pathol. 2009;40:398–404.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Sugao Y, Yao T, Kubo C, Tsuneyoshi M. Improved prognosis of solid-type poorly differentiated colorectal adenocarcinoma: a clinicopathological and immunohistochemical study. Histopathology. 1997;31:123–33.PubMedCrossRef Sugao Y, Yao T, Kubo C, Tsuneyoshi M. Improved prognosis of solid-type poorly differentiated colorectal adenocarcinoma: a clinicopathological and immunohistochemical study. Histopathology. 1997;31:123–33.PubMedCrossRef
16.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging handbook. 7th ed. New York: Springer, 2010:173–206. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging handbook. 7th ed. New York: Springer, 2010:173–206.
17.
Zurück zum Zitat Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol. 2013;37:1592–1602.PubMedCentralPubMedCrossRef Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol. 2013;37:1592–1602.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Toon CW, Chou A, DeSilva K, Chan J, Patterson J. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol. 2013;27:644–50.PubMedCentralPubMedCrossRef Toon CW, Chou A, DeSilva K, Chan J, Patterson J. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol. 2013;27:644–50.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Bullock M, O’Neill C, Chou A, Clarkson A. Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinoma. Endocr Relat Cancer. 2012;19:779–84.PubMedCrossRef Bullock M, O’Neill C, Chou A, Clarkson A. Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinoma. Endocr Relat Cancer. 2012;19:779–84.PubMedCrossRef
20.
Zurück zum Zitat Hall G, Clarkson A, Shi A, Langford E, Leung H. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology. 2010;42:409–13.PubMedCrossRef Hall G, Clarkson A, Shi A, Langford E, Leung H. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology. 2010;42:409–13.PubMedCrossRef
22.
Zurück zum Zitat Chou A, Toon CW, Clarkson A, et al. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol. 2014;45(8):1697–1703.PubMedCrossRef Chou A, Toon CW, Clarkson A, et al. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol. 2014;45(8):1697–1703.PubMedCrossRef
23.
25.
Zurück zum Zitat Gafà R, Maestri I, Matteuzzi M, Santini A, Ferretti S. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer. 2000;89:2025–37.PubMedCrossRef Gafà R, Maestri I, Matteuzzi M, Santini A, Ferretti S. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer. 2000;89:2025–37.PubMedCrossRef
26.
Zurück zum Zitat Rosty C, Williamson EJ, Clendenning M, et al. Should the grading of colorectal adenocarcinoma include microsatellite instability status? Hum Pathol. 2014;45(10):2077–84.PubMedCrossRef Rosty C, Williamson EJ, Clendenning M, et al. Should the grading of colorectal adenocarcinoma include microsatellite instability status? Hum Pathol. 2014;45(10):2077–84.PubMedCrossRef
27.
Zurück zum Zitat Ogino S, Shima K, Meyerhardt JA, McCleary NJ. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clinical Cancer Res. 2012;18(3):890–900.CrossRef Ogino S, Shima K, Meyerhardt JA, McCleary NJ. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clinical Cancer Res. 2012;18(3):890–900.CrossRef
Metadaten
Titel
Medullary Colorectal Carcinoma Revisited: A Clinical and Pathological Study of 102 Cases
verfasst von
Robert D. Knox, MBBS
Nathan Luey, BSc
Loretta Sioson, BSc
Andrew Kedziora, FRCPA
Adele Clarkson, BSc
Nicole Watson
Christopher W. Toon, FRCPA
Carmen Cussigh
Stuart Pincott, FRACS
Stephen Pillinger, FRACS
Yasser Salama, FRACS
Justin Evans, FRACS
John Percy, FRACS
Margaret Schnitzler, PhD, FRACS
Alexander Engel, PhD, FRACS
Anthony J. Gill, MD, FRCPA
Publikationsdatum
01.09.2015
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2015
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4355-5

Weitere Artikel der Ausgabe 9/2015

Annals of Surgical Oncology 9/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.